ArticleCancer cell2023
Challenges and opportunities for modeling aging and cancer.
Abstract read
In one paragraph
Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Dilating the aging clock with light.Innovation (Cambridge (Mass.)) · 2026Review
- Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy.Nature communications · 2026Article
- Spatially controlled induction and regression of basal cell carcinoma, visualized by serial imaging in young and old mice.JID innovations : skin science from molecules to population health · 2026Article
- Organoid: a promising solution to current challenges in cancer immunotherapy.npj biomedical innovations · 2025Review
- Family participation in dignity interventions for patients with cancer receiving palliative care: A scoping review.Asia-Pacific journal of oncology nursing · 2025Review
- Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025Review
- The geroprotective potential of chalcones.Nature communications · 2025Review
- Aging-induced semaphorin 7a promotes TGF-β1-mediated cell plasticity and breast tumor metastases.Cell reports · 2025Article
- Weight Loss Reverses the Effects of Aging and Obesity on Mammary Tumor Immunosuppression and Progression.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems.Lab on a chip · 2025Review
- Global, regional, and national burden of neuroblastoma and peripheral nervous system tumours in individuals aged over 60 from 1990 to 2021: a trend analysis of global burden of disease study.Journal of health, population, and nutrition · 2025Article
- Immunosenescence promotes cancer development: from mechanisms to treatment strategies.Cell communication and signaling : CCS · 2025Review
- The complex interplay between aging and cancer.Nature aging · 2025Review
- Machine learning reveals CAT gene as a novel potential diagnostic and prognostic biomarker in non-small cell lung cancer.Discover oncology · 2024Article
- Family participation in dignity interventions for patients with cancer receiving palliative care: a scoping review protocol.BMJ open · 2024Article
- Decoding senescence of aging single cells at the nexus of biomaterials, microfluidics, and spatial omics.npj aging · 2024Review
- Exploring the molecular and immune landscape of cellular senescence in lung adenocarcinoma.Frontiers in immunology · 2024Article
- Methylation across the central dogma in health and diseases: new therapeutic strategies.Signal transduction and targeted therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Olga AnczukówThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Electronic address: olga.anczukow@jax.org.
Susie AirhartThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Jeffrey H ChuangThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Lisa M CoussensDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
George A KuchelUConn Center on Aging, University of Connecticut School of Medicine, Farmington, CT, USA.
Ron KorstanjeThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Sheng LiThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Anna Lisa LucidoThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Sandra S McAllisterDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA.
Katerina PolitiDepartments of Pathology, and Medicine (Section of Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA.
Kornelia PolyakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; The Broad Institute of MIT and Harvard, Cambridge, MA, USA; The Ludwig Center at Harvard, Boston, MA, USA; Harvard Stem Cell Institute, Cambridge, MA, USA.
Timothy RatliffDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA.
Gary RenThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Jennifer J TrowbridgeThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Duygu UcarThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Karolina PaluckaThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Electronic address: karolina.palucka@jax.org.
Funding
Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9MUnderstanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5MTransgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI Andrea L Kasinski · 1985 to 2026
$43.4MTranslational CoreP30AG038070 · NIA · JACKSON LABORATORY · PI Gary A Churchill · 2010 to 2026
$19.3MThe KAPP-Sen Tissue Mapping Center CollaborativeU54AG075941 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI GAROVIC, VESNA D, KUCHEL, GEORGE A · 2021 to 2025
$13.8MTargeting intratumor heterogeneity in breast cancerR35CA197623 · NCI · DANA-FARBER CANCER INST · PI KORNELIA POLYAK · 2015 to 2026
$12.4MResearch Education ComponentP30AG067988 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Richard H Fortinsky, GEORGE A KUCHEL · 2021 to 2026
$9.5MA deep longitudinal analysis of next generation influenza vaccines in older adultsU01AI165452 · NIAID · JACKSON LABORATORY · PI Adolfo Garcia-Sastre, GEORGE A KUCHEL · 2022 to 2026
$9.0MTranslational Geroscience NetworkR33AG061456 · NIA · MAYO CLINIC ROCHESTER · PI JAMES L. KIRKLAND, STEPHEN B. KRITCHEVSKY · 2019 to 2026
$6.2MNSAIDs During Postpartum Involution for Breast Cancer ChemopreventionR01CA169175 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHEDIN, PEPPER J · 2013 to 2024
$4.8MDeveloping Effective Approaches to Extend Hematopoietic Healthspan by Targeting Cell-Extrinsic and Cell-Intrinsic Alterations at Middle AgeR01DK118072 · NIDDK · JACKSON LABORATORY · PI Jennifer Jean Trowbridge · 2018 to 2026
$4.2M(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast CancerR01CA219880 · NCI · JACKSON LABORATORY · PI PALUCKA, ANNA KAROLINA · 2017 to 2021
$3.4MNCI NIH HHS P30 CA023168NCI NIH HHS P30 CA034196NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA169175NCI NIH HHS R01 CA219880NCI NIH HHS R01 CA223150NCI NIH HHS R01 CA230031NCI NIH HHS R01 CA248317NCI NIH HHS R21 CA184851NCI NIH HHS R35 CA197623NCI NIH HHS U01 CA224012NCI NIH HHS U01 CA269409NCI NIH HHS U01 CA271830NIAID NIH HHS R01 AI142086NIAID NIH HHS U01 AI165452NIA NIH HHS P30 AG038070NIA NIH HHS P30 AG067988NIA NIH HHS R01 AG069010NIA NIH HHS R13 AG069519NIA NIH HHS R33 AG061456NIA NIH HHS U01 AG077925NIA NIH HHS U54 AG075941NIDDK NIH HHS R01 DK118072NIDDK NIH HHS R01 DK126478NIDDK NIH HHS R56 DK112947NIGMS NIH HHS R01 GM138541
Abstract
Age is among the main risk factors for cancer, and any cancer study in adults is faced with an aging tissue and organism. Yet, pre-clinical studies are carried out using young mice and are not able to address the impact of aging and associated comorbidities on disease biology and treatment outcomes. Here, we discuss the limitations of current mouse cancer models and suggest strategies for developing novel models to address these major gaps in knowledge and experimental approaches.
Indexed as
AgingNeoplasmsAnimalsDisease Models, AnimalMiceRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.